HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Esther Sanfeliu(Hospital Clínic de Barcelona), Patricia Villagrasa, Federica Miglietta(University of Padua), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), Benedetta Conte(Ospedale Policlinico San Martino), Joel S. Parker(University of North Carolina at Chapel Hill), Tommaso Giarratano(Istituto Oncologico Veneto), Patricia Galván(Vall d'Hebron Institute of Oncology), Charles M. Perou(University of North Carolina at Chapel Hill), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Julia Maués, Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ana Vivancos(Vall d'Hebron Institute of Oncology), Laura Angelats(Hospital Clínic de Barcelona), Núria Chic(Breast Cancer Research Foundation), Gaia Griguolo(University of North Carolina at Chapel Hill), Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Vidal(Inserm), Aleix Prat(Hospital Clínic de Barcelona), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k